Parents are interested in newborn genomic testing during the early postpartum period

Susan E Waisbren, Danielle K Bäck, Christina Liu, Sarah S Kalia, Steven A Ringer, Ingrid A Holm, Robert C Green, Susan E Waisbren, Danielle K Bäck, Christina Liu, Sarah S Kalia, Steven A Ringer, Ingrid A Holm, Robert C Green

Abstract

Purpose: We surveyed parents to ascertain interest in newborn genomic testing and determine whether these queries would provoke refusal of conventional state-mandated newborn screening.

Methods: After a brief genetics orientation, parents rated their interest in receiving genomic testing for their healthy newborn on a 5-point Likert scale and answered questions about demographics and health history. We used logistic regression to explore factors associated with interest in genomic testing and tracked any subsequent rejection of newborn screening.

Results: We queried 514 parents within 48 hours after birth while still in hospital (mean age (SD) 32.7 (6.4) years, 65.2% female, 61.2% white, 79.3% married). Parents reported being not at all (6.4%), a little (10.9%), somewhat (36.6%), very (28.0%), or extremely (18.1%) interested in genomic testing for their newborns. None refused state-mandated newborn screening. Married participants and those with health concerns about their infant were less interested in newborn genomic testing (P = 0.012 and P = 0.030, respectively). Degree of interest for mothers and fathers was discordant (at least two categories different) for 24.4% of couples.

Conclusion: Interest in newborn genomic testing was high among parents of healthy newborns, and the majority of couples had similar levels of interest. Surveying parents about genomic sequencing did not prompt rejection of newborn screening.Genet Med 17 6, 501-504.

Conflict of interest statement

DISCLOSURES

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Parental interest, immediately after birth, in hypothetical newborn genomic testing for their newborns as part of a research study.

References

    1. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370:2418–2425.
    1. Green RC, Rehm HL, Kohane IS. Clinical genome sequencing. In: Ginsburg GS, Willard HF, editors. Genomic and Personalized Medicine. 2. Vol. 1. San Diego: Academic Press; 2013. pp. 102–122.
    1. Landau YE, Lichter-Konecki U, Levy HL. Genomics in newborn screening. J Pediatr. 2014 Jan;164(1):14–19.
    1. Tarini BA, Goldenberg AJ. Ethical issues with newborn screening in the genomics era. Annu Rev Genomics Hum Genet. 2012 Sep 22;13:381–393.
    1. Goldenberg AJ, Sharp RR. The ethical hazards and programmatic challenges of genomic newborn screening. JAMA. 2012 Feb 1;307(5):461–462.
    1. Knoppers BM, Senecal K, Borry P, Avard D. Whole-genome sequencing in newborn screening programs. Science Translational Medicine. 2014;6(229)
    1. Levy HL. Newborn screening: The genomic challenge. Mol Genet Genomic Med. 2014 Mar;2(2):81–84.
    1. Gonzales JL. Ethics for the pediatrician: Genetic testing and newborn screening. Pediatr Rev. 2011 Nov;32(11):490–493.
    1. Hasegawa LE, Fergus KA, Ojeda N, Au SM. Parental attitudes toward ethical and social issues surrounding the expansion of newborn screening using new technologies. Public Health Genomics. 2011;14(4–5):298–306.
    1. Etchegary H, Dicks E, Hodgkinson K, Pullman D, Green J, Parfey P. Public attitudes about genetic testing in the newborn period. Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN / NAACOG. 2012 Mar;41(2):191–200.
    1. Goldenberg AJ, Dodson DS, Davis MS, Tarini BA. Parents’ interest in whole-genome sequencing of newborns. Genet Med. 2013;16(1):78–84.
    1. Valakkathi V. Newborn screening in America: Problems and policies. Council for Responsible Genetics. 2012
    1. Feuchtbaum L, Cunningham G, Sciortino S. Questioning the need for informed consent: A case study of California’s experience with a pilot newborn screening research project. Journal of Empirical Research on Human Research Ethics : JERHRE. 2007 Sep;2(3):3–14.
    1. Bombard Y, Miller FA, Hayeems RZ, et al. Public views on participating in newborn screening using genome sequencing. Eur J Hum Genet. 2014
    1. Brown AJ, MacKenzie J, Fitch M, Estell A, Aitken D. Impact of obtaining signed consent for newborn screening tests in Scotland. Paper presented at: Association of Clinical Biochemists National Meeting; 2004.
    1. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003 Nov 19;290(19):2564–2572.
    1. Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis. 2006 Aug 17;29:677–682.
    1. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: The effect of a false-positive result. Pediatrics. 2006;117:1915–1921.
    1. Waisbren SE. Newborn screening for metabolic disorders. JAMA. 2006 Aug 23;296(8):993–995.
    1. Lipstein EA, Perrin JM, Waisbren SE, Prosser LA. Impact of false-positive newborn metabolic screening results on early health care utilization. Genet Med. 2009 Oct;11(10):716–721.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する